^
Association details:
| Biomarker: | MET exon 14 mutation + KRAS G12A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer
Published date:
05/27/2020
Excerpt:
In two patients with progressive disease, genomic profiling demonstrated a cMET exon 14 mutation + KRAS G12A mutation in one case, and a persisting ROS1-CD74 fusion + TP53 K139N, FGFR2 E250G, ATM G2695D, and NF1 R2258Q mutations in the other.
DOI:
10.1007/s12094-020-02376-w
